Repurposing of Food and Drug Admnistration (FDA) approved library to identify a potential inhibitor of for developing an antileishmanial agent.

Leishmaniasis is one of the top 10 neglected tropical diseases. Globally, it impacts more than 12 million individuals. In light of the absence of a safer, affordable treatment for the Leishmaniasis, along with therapeutic failures and drug resistance, novel therapeutic strategies are necessary to discover new drugs.